Choosing BTKi or BCL2i or Combination Therapy for 1L CLL

Danielle Brander

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Clinical Practice Updates in CLL/SLL

Integrity CE

M. Cortese, D. Wallace, A. Niu

1L Therapy in CLL: What Are the Best Options?

SOHO Brazil 2024

J. Burger

Debates in CLL: Continuous or Finite Duration Therapy

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Jain

3L in CLL: The Best Options in a Patient Double-Refractory to Covale…

SOHO Brazil 2024

J. Burger

ASH 2024 Insights: Ph 3 AMPLIFY - Fixed-Duration Acalabrutinib + Ven…

2024 ASH Annual Meeting Insights Hub

J. Brown

Sequencing Therapies in CLL: The Importance of First-Line Treatment …

Nicole Lamanna

ASH 2024 Insights: Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen…

2024 ASH Annual Meeting Insights Hub

J. Soumerai

CLL Treatment Sequencing: The Importance of First Choice

City of Hope

S. Rosen

Practice-Changing Updates in Indolent B-Cell Lymphomas

Massachusetts General Hospital Cancer Center

J. Soumerai

Year in Review 2024: CLL Highlights

The University of Kansas Cancer Center

M. Hoffmann

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Pirtobrutinib in CLL: Current and Potential Utility in the Treatment…

Nicole Lamanna

Guideline-Based Treatment Approaches in CLL

Farrukh Awan

Single vs. Multiple Agents in 2L Therapy for CLL

SOHO Brazil 2024

J. Burger

Experts Discuss Highlights and Key Takeaways in CLL From ASCO® and E…

2024 ASCO® Annual Meeting Insights Hub

K. Rogers, J. Woyach

Venetoclax vs. BTKis in CLL Treatment

City of Hope

A. Danilov

ASH 2024 Insights: Sonrotoclax + Zanubrutinib in 1L CLL - Results Fr…

2024 ASH Annual Meeting Insights Hub

J. Soumerai

ASH 2024 Insights: Zanubrutinib in Acalabrutinib-Intolerant Patients…

2024 ASH Annual Meeting Insights Hub

M. Shadman